Corpus Intelligence IC Memo — JOHN DEMPSEY HOSPITAL 2026-04-26 03:51 UTC
IC Memo — JOHN DEMPSEY HOSPITAL
Investment Committee Memorandum | CT | 141 beds | Grade B | EBITDA uplift $43.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

JOHN DEMPSEY HOSPITAL

CCN 070036 | HARTFORD, CT | 141 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

JOHN DEMPSEY HOSPITAL is a 141-bed suburban community hospital in HARTFORD, CT with $590.3M in net patient revenue and a -24.8% operating margin. The hospital serves a payer mix of 26.6% Medicare, 22.6% Medicaid, and 50.8% commercial.

Thesis: Undervalued. Our ML models identify $43.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -24.8% to -17.5% (+736bps).

Net Revenue HCRIS$590.3M
Current EBITDA COMPUTED$-146.6M
Operating Margin COMPUTED-24.8%
Occupancy HCRIS85.4%
Revenue / Bed COMPUTED$4.2M
Net-to-Gross HCRIS33.4%
Distress Probability ML40.7%

2. Market Context & Competitive Position

39
CT Hospitals
-6.8%
State Median Margin
19
Comparable Hospitals

CT has 39 Medicare-certified hospitals with a median operating margin of -6.8%. The target's margin of -24.8% places it below the state median. Among 19 size-comparable peers (70-282 beds), the median margin is -6.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (70-282), prioritizing same-state peers. 19 hospitals in the comp set.

HospitalStateBedsRevenueMargin
JOHN DEMPSEY HOSPITAL (Target)CT141$590.3M-24.8%
THE HOSPITAL OF CENTRAL CONNECCT244$541.8M-5.6%
GREENWICH HOSPITALCT186$498.0M-5.9%
ST. VINCENTS MEDICAL CENTERCT211$481.3M-12.7%
MIDDLESEX HOSPITALCT186$449.7M-1.3%
LAWRENCE & MEMORIAL HOSPITALCT236$422.7M-6.7%
CONNECTICUT CHILDRENS MEDICAL CT187$416.8M-6.7%
THE WILLIAM W. BACKUS HOSPITALCT172$411.7M-4.3%
MIDSTATE MEDICAL CENTERCT143$346.8M-2.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $43.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$12.4M+210bp18mo
Cost to Collect4.5%2.5%$11.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$11.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$7.2M+122bp9mo
Clean Claim Rate88.0%96.0%$378K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$12.4M
Cost to Collect
$11.8M
Denial Rate Reduction
$11.7M
A/R Days Reduction
$7.2M
Clean Claim Rate
$378K
Total EBITDA Uplift$43.4M
Current EBITDA$-146.6M
+ RCM Uplift+$43.4M
Pro Forma EBITDA$-103.2M
Current Margin-24.8%
Pro Forma Margin-17.5%
WC Released (1x)$22.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-225.6M$-532.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-225.6M$-659.3M0.00x-100.0%
Bull Case9.0x11.0x$-203.0M$-589.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-203.0M$-702.7M0.00x-100.0%
Bear Case11.0x10.0x$-248.2M$-676.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-248.2M$-825.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (22.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 19 hospitals with 70-282 beds
  • Same-state prioritization (n=20)
  • Comp margins: P25=-10.6% / P50=-6.7% / P75=-5.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.